Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

Nov. 16, 2000

Independent safety board recommends continuation of Theratope vaccine phase III trial

Nov. 15, 2000

York Medical acquires Norelin from Biostar

Nov. 14, 2000

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Nov. 10, 2000

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

KS Biomedix and York Medical sign high-affinity antibody deal

Nov. 7, 2000

KRN-7000 as an adjunct to surgical removal of tumors

Nov. 3, 2000

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...